Keywords: tavocept, increases, survival, days, usa, bionumerik, pharmaceuticals

Tavocept increases survival by 198 days

Article | 28 July 2008

Print This

The USA's BioNumerik Pharmaceuticals says that adenocarcinoma patients in a Phase II trial of Tavocept showed a survival increase of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in